Prostate cancer vaccines: Current status and future potential

BioDrugs

Volumn 22, Issue 2, 2008, Pages 71-84

  Doehn, Christian ^a   Böhmer, Torsten ^a   Kausch, Ingo ^a   Sommerauer, Martin ^a   Jocham, Dieter ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Prostate cancer; Prostate cancer vaccine, general; Research and development

Indexed keywords

BCG VACCINE; BEVACIZUMAB; DCVAX; DENDRITIC CELL VACCINE; DEXAMETHASONE; DNA VACCINE; DOCETAXEL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERLEUKIN 2; METRONIDAZOLE; NILUTAMIDE; ONYVAX P; PEPTIDE VACCINE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROSTVAC; PROSTVAC VF; PROVENGE; TUMOR CELL VACCINE; TUMOR VACCINE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ALLERGIC REACTION; ANTIBODY PRODUCTION; B LYMPHOCYTE; BRAIN ISCHEMIA; CANCER CELL CULTURE; CANCER GROWTH; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELL ACTIVATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DELAYED HYPERSENSITIVITY; DOWN REGULATION; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG WITHDRAWAL; EDEMA; ENZYME LINKED IMMUNOSPOT ASSAY; ERYTHEMA; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNE SYSTEM; IMMUNOTHERAPY; INJECTION SITE REACTION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEINURIA; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; T LYMPHOCYTE; TREATMENT FAILURE; TUMOR ESCAPE; UNSPECIFIED SIDE EFFECT; VACCINIA VIRUS;

EID: 40949084808     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200822020-00001     Document Type: Review

References (74)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66
2. Brenner H, Arndt V. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis. J Clin Oncol 2005; 23: 441-7
3. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7
4. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12
5. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089-94
6. Guinan P, Bush IM, John T, et al. B.C.G. immunotherapy in carcinoma of prostate. Lancet 1973; 25: 443-4
7. Merrin C, Han T, Klein E, et al. Immunotherapy of prostatic cancer with Bacillus Calmette-Guerin and purified protein derivative: preliminary results. Urology 1973; 2: 651-4
8. Talwar GP, Singh O, Pal R, et al. Vaccines for control of fertility and hormone dependent cancers. Int J Immunopharmacol 1992; 14: 511-4
9. Thau R. Anti-LHRH and anti-pituitary gonadotropin vaccines: their development and clinical applications. Scand J Immunol Suppl 1992; 11: 127-30
10. Sanda MG, Ayyagari SR, Jaffee EM, et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 1994; 151: 622-8
11. Simons JW, Mikhak B, Chang JF, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999; 59: 5160-8
12. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18: 3894-903
13. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2: 52-8
14. Ragde H, Cavanagh WA, Tjoa BA. Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. J Urol 2004; 172: 2532-8
15. Ridgway D. The first 1000 dendritic cell vaccines. Cancer Invest 2003; 21: 873-86
16. Totterman TH, Loskog A, Essand M. The immunotherapy of prostate and bladder cancer. BJU Int 2005; 96: 728-35
17. Miller A, Pisa P. Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother 2007; 56: 81-7
18. Tien AH, Xu L, Helgason CD. Altered immunity accompanies disease progression in a mouse model of prostate dysplasia. Cancer Res 2005; 65: 2947-55
19. Healy CG, Simons JW, Carducci MA, et al. Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry 1998; 32: 109-19
20. Webster WS, Small EJ, Rini BI, et al. Prostate cancer immunology: biology, therapeutics, and challenges. J Clin Oncol 2005; 23: 8262-9
21. Ward S, Casey D, Labarthe MC, et al. Immunotherapeutic potential of whole tumor cells. Cancer Immunol Immunother 2002; 51: 351-7
22. Tarassoff CP, Arlen PM, Gulley JL. Therapeutic vaccines for prostate cancer. Oncologist 2006; 11: 451-62
23. MacRae EJ, Giannoudis A, Ryan R, et al. Gene therapy for prostate cancer: current strategies and new cell-based approaches. Prostate 2006; 66: 470-94
24. Slovin SF. Emerging role of immunotherapy in the management of prostate cancer. Oncology (Williston Park) 2007; 21: 326-33
25. Hodge JW, Abrahams S, Schlom J, et al. Induction of antitumor immunity by recombinant vaccinia viruses B7-1 or B7-2 costimulatory molecules. Cancer Res 1994; 54: 5552-5
26. Hobeika AC, Clay TM, Mosca PJ, et al. Quantitating therapeutically relevant T cell response to cancer vaccines. Crit Rev Immunol 2001; 21: 287-97
27. DiPaola R, Plante M, Kaufman H, et al. A phase I trial of pox PSA vaccines (PROSTVAC®-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOMTM) in patients with prostate cancer. J Transl Med 2006; 4: 1-5
28. Simons J, Nelson W, Nemunaitis J, et al. Phase II trials of a GM-CSF gene-transduced prostate cancer cell line vaccine (GVAX®) in hormone refractory prostate cancer [abstract]. Am Soc Clin Oncol 2002; 21: 183a
29. Simons JW, Higano C, Smith D, et al. Clinical and immunologic findings in a phase 2 study of a GM-CSF-secreting prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer (met HPRC) [abstract]. J Clin Oncol 2005; 23: 170s
30. Small E, Higano C, Smith D, et al. Analysis of prognostic variables in phase II trials of GVAX® vaccine for prostate cancer in metastatic hormone refractory prostate cancer [abstract]. ASCO 2006 Prostate Cancer Symposium; 2006 Feb 24-26; San Francisco (CA), 220
31. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21: 1232-7
32. GVAX® vaccine for prostate cancer vs docetaxel & prednisone in patients with metastatic hormone-refractory prostate cancer [ClinicalTrials.gov identifier: NCT00089856]. ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00089856 [Accessed 2007 Aug 10]
33. Docetaxel in combination with GVAX® immunotherapy versus docetaxel and prednisone in prostate cancer patients [ClinicalTrials.gov identifier: NCT00133224]. ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00133224 [Accessed 2007 Aug 10]
34. Higano CS, Burch PA, Small EJ, et al. Immunotherapy (APC8015) for androgen independent prostate cancer (AIPC): final progression and survival data from a second phase 3 trial [abstract]. Eur J Cancer 2005; 3 Suppl.: PS1
35. Provenge® (Sipuleucel-T) active cellular immunotherapy treatment of metastatic prostate cancer after failing hormone therapy [ClinicalTrials.gov identifier: NCT00065442]. ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00065442 [Accessed 2007 Aug 10]
36. Doehn C, Böhmer T, Jocham D. Technology evaluation: Onyvax-P, Onyvax. Curr Opin Mol Ther 2005; 7: 511-9
37. Michael A, Ball G, Quatan N, et al. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 2005; 11: 4469-78
38. Eaton JD, Perry MJ, Nicolson S, et al. Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer. BJU Int 2002; 89: 19-26
39. Michael A, Quatan N, Whelan M, et al. Preliminary results of a phase I/II study to determine the safety, tolerability and efficacy of the allogeneic whole cell vaccine in patients with hormone refractory prostate cancer [abstract]. Proc Am Soc Clin Oncol 2003; 22: 188
40. Dalgleish AG, Quatan N, Michael A, et al. Increased time to progression and sustained PSA velocity responses in a phase II trial in advanced metastatic prostate cancer following treatment with ONY-P1, an allogeneic whole cell vaccine [abstract]. J Clin Oncol 2005; 23 (16S): 434s
41. ONY-P for the treatment of prostate cancer [trial no. ONY-P1-06-01; ClinicalTrials.gov Identifier: NCT00514072]. Onyvax [online]. Available from URL: http://www.onyvax.com/html/clinical_trials/0/index.html [Accessed 2007 Aug 10]
42. Rini BI, Weinberg V, Fong L, et al. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (Provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 2006; 107: 67-74
43. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-34
44. Knutson KL. Technology evaluation: DCVax, Northwest Biotherapeutics. Curr Opin Mol Ther 2002; 4: 403-7
45. Murphy GP, Tjoa BA, Simmons SJ, et al. Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 1999; 39: 54-9
46. Tjoa BA, Simmons SJ, Elgamal A, et al. Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 1999; 40: 125-9
47. Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immun Rev 2004; 199: 251-63
48. Heiser A, Dahm P, Yancey DR, et al. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol 2000; 164: 5508-14
49. Heiser A, Coleman D, Dannull J, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002; 109: 409-17
50. Hess PR, Boczkowski D, Nair SK, et al. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. Cancer Immunol Immunother 2006; 55:672-83
51. Kyte JA, Gaudernack G. Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. Cancer Immunol Immunother 2006; 55: 1432-42
52. Perambakam S, Hallmeyer S, Reddy S, et al. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide. Cancer Immunol Immunother 2006; 55: 1033-42
53. Neumanitis J. Selective replicating viral vectors. Biodrugs 2003; 17: 251-62
54. Gardlik R, Palffy R, Hodosy J, et al. Vectors and delivery systems in gene therapy. Med Sci Mont 2005; 11: RA110-21
55. Eder JP, Kantoff PW, Roper K, et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in avanced prostate cancer. Clin Cancer Res 2000; 6: 1632-8
56. Gulley JL, Dahut W, Chen A, et al. A phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with androgen independent prostate cancer (AIPC) [abstract]. Proc Am Soc Clin Oncol 2001; 20: 273a
57. Doehn C, Kausch I, Böhmer T, et al. rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccine, Therion. Curr Opin Mol Ther 2007; 9: 183-9
58. Gulley J, Chen AP, Dahut W, et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 2002; 53: 109-17
59. Arlen PM, Gulley JL, Todd N, et al. Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol 2005; 174: 539-46
60. Kaufman HL, Wang W, Manola J, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004; 22: 2122-32
61. Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005; 11: 3353-62
62. Arlen PM, Gulley JL, Parker C, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006; 12: 1260-9
63. Arlen PM, Gulley J, Dahut W, et al. A phase I study of sequential vaccinations with recombinant Fowlpox-PSA (L155)-TRICOM (rF)alone, or in combination with recombinant vaccinia-PSA (L155)-TRICOM (rV), and the role of GM-CSF, in patients (Pts) with prostate cancer [abstract]. Proc Am Soc Clin Oncol 2004; 22 (14S): 168
64. Roos AK, Pavlenko M, Charo J, et al. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine. Prostate 2005; 62: 217-23
65. Miller AM, Ozenci V, Kiessling R, et al. Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer. J Immunother 2005; 28: 389-95
66. Wolchok JD, Gregor PD, Nordquist LT, et al. DNA vaccines: an active immunization strategy for prostate cancer. Semin Oncol 2003; 30: 659-66
67. Butterfield LH, Ribas A, Dissette VB, et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 2003; 9: 998-1008
68. Kudo-Saito C, Schlom J, Hodge JW. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses. Clin Cancer Res 2005; 11: 2416-26
69. McArdle PA, McMillan DC, Sattar N, et al. The relationship between interleukin-6 and C-reactive protein in patients with benign and malignant prostate disease. Br J Cancer 2004; 91: 1755-7
70. Adler AJ. Mechanisms of T cell tolerance and suppression in cancer mediated by tumor-associated antigens and hormones. Curr Cancer Drug Targets 2007; 7: 3-14
71. Li CY, Huang Q, Kung HF. Cytokine and immuno-gene therapy for solid tumors. Cell Mol Immunol 2005; 2: 81-91
72. Keilholz U, Weber J, Finke JH, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002; 25: 97-138
73. Keilholz U, Martus P, Scheibenbogen C. Immune monitoring of T cell responses in cancer vaccine development. Clin Cancer Res 2006; 12: 2346s-52s
74. Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer 2005; 41: 858-87